Big Money Sentiment decreased to 0.86 in Q4 2018. It has change of 0.94, from 2018Q3’s 1.8. The ratio turned negative due to TherapeuticsMD, Inc. positioning: 24 sold and 39 reduced. 15 funds amassed holdings and 39 increased holdings. Investors holded 174.81 million in 2018Q3 but now own 183.38 million shares or 4.90% more.
Citadel Advsrs Ltd Llc invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Cetera Advsrs Limited Company holds 0.02% of its capital in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 68,275 shs. Amalgamated Commercial Bank has 26,314 shs. Jefferies Group Limited Liability Com invested 0% of its capital in TherapeuticsMD, Inc. (NASDAQ:TXMD). Blackrock holds 0% or 16.69M shs in its capital. Metropolitan Life Ins holds 0% or 56,279 shs in its capital. 102,873 were accumulated by Rice Hall James & Associate Ltd Liability. Natixis L P reported 177,941 shs. Alpine Woods Invsts Ltd Llc has 17,000 shs. Pub Employees Retirement Association Of Colorado holds 0.04% in TherapeuticsMD, Inc. (NASDAQ:TXMD) or 1.34 million shs. 1492 Limited Company accumulated 699,846 shs or 2.39% of the stock. 15,000 were accumulated by Weiss Multi. Voya Invest Mgmt Ltd Liability owns 3.03M shs for 0.03% of their capital. 99,877 are owned by Proshare Advisors Lc. State Of Wisconsin Invest Board has invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD).

TherapeuticsMD, Inc. had 17 sales and 0 insider buys since October 9, 2018. This’s net activity of $15.31 million. Finizio Robert G also sold $889,088 worth of TherapeuticsMD, Inc. (NASDAQ:TXMD) shs. 182,800 shs were sold by Bernick Brian, worth $891,333. 40,000 shs were sold by Cartwright Daniel A, worth $182,800.

Investors expect TherapeuticsMD, Inc. (NASDAQ:TXMD)’s quarterly earnings on May, 2., RTT reports. Analysts expect change of 45.45 % or $0.05 from previous year’s $-0.11 EPS compared to current’s $-0.16 EPS. Analysts at Wall Street see TherapeuticsMD, Inc.’s -5.88 % EPS growth compared to $-0.17 EPS for last quarter. TXMD is hitting $4.91 during the last trading session, after decreased 0.81%.Currently TherapeuticsMD, Inc. is uptrending after 18.64% change in last April 8, 2018. TXMD has also 2.18 million shares volume. TXMD outperformed the S&P 500 by 14.27%.

TherapeuticsMD, Inc. operates as a women's health care product company.The company has $1.18 billion market cap. The firm makes and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name.Last it reported negative earnings. The Company’s pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

For more TherapeuticsMD, Inc. (NASDAQ:TXMD) news released briefly go to: Businesswire.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “TherapeuticsMD Announces Oral and Poster Presentations on BIJUVAâ„¢ and ANNOVERAâ„¢ at the Endocrine Society 2019 Annual Meeting – Business Wire” released on March 25, 2019, “TherapeuticsMD Reports Strong Launch For Imvexxy – Seeking Alpha” on November 19, 2018, “TherapeuticsMD Q4 Earnings Preview – Seeking Alpha” with a publish date: February 20, 2019, “Invexxy launch results buoy TherapeuticsMD, up 11% – Seeking Alpha” and the last “TherapeuticsMD (TXMD) Shares Cross Above 200 DMA – Nasdaq” with publication date: February 26, 2019.